Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 3/20 | 0.42 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149676 | 0.93 | HIPK2 (0.44) | SMYD3CYP3A4IMPDH2ARHIPK2 | |
| SCHEMBL16722810 | 0.84 | CES2 (0.46) | CYP3A4 | |
| SCHEMBL3126130 | 0.81 | IMPDH2 (0.53) | SMYD3CYP3A4IMPDH2ARHIPK2 | |
| SCHEMBL4353066 | 0.80 | CYP19A1 (0.47) | SMYD3CYP3A4IMPDH2ARHIPK2 | |
| SCHEMBL113378 | 0.79 | SMYD3 (0.55) | SMYD3CYP3A4IMPDH2ARHIPK2 | |
| SCHEMBL29489099 | 0.79 | SMYD3 (0.55) | SMYD3CYP3A4IMPDH2ARHIPK2 | |
| SCHEMBL29522657 | 0.77 | AR (0.62) | SMYD3CYP3A4IMPDH2ARHIPK2 | |
| SCHEMBL12765931 | 0.77 | SMYD3 (0.50) | SMYD3CYP3A4IMPDH2ARHIPK2 | |
| SCHEMBL4280154 | 0.77 | AR (0.62) | SMYD3CYP3A4IMPDH2ARHIPK2 | |
| Hydrochloric Acid SCHEMBL7557776 | 0.77 | SMYD3 (0.54) | SMYD3CYP3A4IMPDH2ARHIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181252-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181252-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150152109-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152109-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-8993586-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993586-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150025098-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025098-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-8859773-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859773-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-RE43802-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-11-13 | — | — | US | disclosed |
| US-RE43596-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-RE43596-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC | 2012-05-03 | — | — | US | disclosed |
| US-RE42889-E1 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2011-11-01 | — | — | US | disclosed |
| US-7829564-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2010-11-09 | — | — | US | disclosed |
| US-7531538-B2 | α- and β-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2009-01-22 | — | — | US | disclosed |
| US-7320983-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025098-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | SMYD3 3979/4885CYP3A4 1547/4885IMPDH2 1086/4885 |
| US-20150152109-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | SMYD3 3979/4885CYP3A4 1547/4885IMPDH2 1086/4885 |
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | DNPEP, ASPH, PREP | SMYD3 1821/4885CYP3A4 2857/4885IMPDH2 1888/4885 |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | SMYD3 3979/4885CYP3A4 1547/4885IMPDH2 1086/4885 |
| US-20070078173-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | SMYD3 1821/4885CYP3A4 2857/4885IMPDH2 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.